March 2010
Personalized medicine is proving more than a buzzword as in vitro diagnostics (IVD) companies and clinical laboratories align to launch and implement products designed to aid physicians in offering treatments tailored to individual patients. As yesterday’s biomarker discoveries emerge in today’s multiplex molecular assays, pharmaceutical companies are increasingly prioritizing the collaborative development of companion diagnostics while IVD companies focus on making the case for clinical utility. In this month’s special supplement to DTTR, we highlight a series of recent developments in personalized medicine, from new genetic tests for cancer launched in recent weeks by Genomic Health and Clarient to some landmark studies that may provide the critical research underpinnings for the diagnostic tests of the future.
|
|
|
 Archives
|
|
March 2010 - Table of Contents